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ABSTRACT 
Objectives: Anemia in pregnant women is a common condition, diagnosed when the concentration of hemoglobin falls 
below 11 g/dL. Taking into consideration the accounts of nephrologists about good results of treatment of secondary anemia 
using erythropoietin in patients with renal failure, we tried to use EPO to cure anemia in pregnant women.
The aim of the study was to evaluate the results of EPO treatment on pregnant women diagnosed with iron deficiency 
anemia, as well as possible side effects.
Material and methods: The study consisted of 25 patients:
Group I — treated with iron supplement administered parenterally — Ferrum Lek every two days intramuscularly.
Group II — treated with recombinant human erythropoietin — 1000 j intravenously every three days, with oral iron sup-
plements.
Results: After a week of treatment the positive response was higher in the second group (92.3% in II, vs 33.3% in I, p < 0.005).
The average increase of hemoglobin and RBC was significantly higher in II group.
An increase in hemoglobin did not correlate with the age of women (r = 0.07) or with the duration of pregnancy (r = 0.08). 
However, a negative correlation was found between basic hemoglobin level and its increase after treatment (r = 0.602).
Conclusions: EPO administered with the oral dose of iron in pregnant women with anemia caused by iron deficiency shows 
higher effectiveness than the use of iron preparations parenterally.
The usage of EPO during pregnancy is not related to any dangerous side effects for the mother or fetus.
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INTRODUCTION
Anemia in pregnant women is a commonly diagnosed 
condition, especially in the 2nd and 3rd trimesters. It is 
estimated that in Poland, 30–41% of women suffer from it, 
in the United States, up to 25%, and in Europe, less than 10%. 
It is most commonly found in women from environments 
with low social and economic status [1]. According to the 
WHO (World Health Organization), 11 g% (6.82 mmol/L) of 
hemoglobin in the blood is considered to be the lower limit of 
the normal, independent of the advancement of pregnancy. 
A small degree of anemia is a natural physiological 
phenomenon during pregnancy. It is caused by the 
increased volume of plasma in proportion to the increase 
in the volume of the morphotic blood elements (anemia 
due to “dilution”). Pathological anemia is diagnosed 
when the concentration of hemoglobin falls below 
11 g/dL (according to the WHO). We distinguish three types 
of anemia: mild (10.9–10 g/dL), moderate (9.9–7 g/dL) and 
severe (< 7 g/dL) [2]. The most common cause of anemia 
in pregnant women is iron deficiency, less commonly folic 
acid or vitamin B12 deficiency [1]. It is also often diagnosed 
in multiple pregnancies, in those infected with the HIV 
(human immunodeficiency virus), and in women suffering 
from chronic renal failure. 
Anemia caused by iron deficiency constitutes 
approximately 80% of all cases of anemia [1].
The consequences of anemia during pregnancy include, 
among other things, the following: placental function 
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disorder and related complications (intrauterine growth 
restriction, premature birth, intrauterine fetal demise), 
abnormal uterine activity during birth or post-partum 
atony related to the metabolic process disorders of the 
uterine muscle. There is also an increased risk of perinatal 
infections that result from changes in the immune system. 
Severe circulatory decompensation and DIC (disseminated 
intravascular coagulation) may also occur due to the lack of 
erythrocyte reserve in case of increased bleeding during 
birth. Children born to anemic mothers are often premature, 
and even if they are born on predicted due dates, they 
usually have a lower birth weight, adaptation process 
disorders and deficiency anemia [3].
Due to the most commonly occurring anemia 
pathogenesis during pregnancy, first-line treatment is the 
iron supplementation in the form of an oral preparation 
or parenterally in case of suspected problems with iron 
assimilation from the gastrointestinal tract [3].
Endogenic EPO (erythropoietin) is a glycoprotein with 
a 34 kDa mass composed of 166 amino acids. Its principal 
source are Leydig cells in kidneys (80–90%) and Ito cells 
in the liver (10–20%). Its small amounts are also produced 
in the liver, lungs, testicles, uterus, spleen, lymphocytes, 
megakaryocytes of the brain, and cornea. During fetal life, 
its primary source is the fetus’ liver and placenta [3]. EPO 
coding gene is located on chromosome 7, whereas the 
factor regulating its production is the concentration of 
oxygen in the blood flowing through the kidneys. 
The target spot of the erythropoietin activity is the he-
matopoietic system located in the bone marrow, and its 
principal function is to regulate erythrocyte production. EPO 
has an effect on the target cells through a receptor (EPO-R) 
that belongs to the first family of cytokine receptors. The 
combination of EPO and EPO-R activates tyrosine kinase 
JAK-2, which leads to the activation of genes Bcl-2 and Bcl-XL 
through the cytoplasmic transcription factor STAT5. Those 
genes stop apoptosis of precursor cells of the erythrocytic 
system and stimulate their maturation to the stadium of the 
mature erythrocyte [4, 5]. An increased number of mature 
erythrocytes appears as a result of that. Hypoxia causes 
an increased production of EPO and an increased number 
of red blood cells, which, in the reverse mechanism, causes 
the decrease of synthesis of this cytokine and the decrease 
of its concentration in blood. Taking into consideration the 
accounts of nephrologists about very good results of treat-
ment of secondary anemia using erythropoietin in patients 
with renal failure, research concerning the use of that sub-
stance in pregnant women has been conducted since the 
end of the 20th century [6]. 
The production of human recombinant erythropoietin 
(rHuEpo) through genetic engineering has allowed for its 
practical use in the treatment of anemia. There have also 
been publications regarding its use in pregnant women. 
Not all the aspects of EPO’s activity are known though, 
and some mentions of the potential threats related to its 
application found in literature require research. It should 
be remembered that there is a limited number of academic 
papers considering this topic and as a result the population 
of this study is also limited. 
Aim of the study
The objective of the conducted research was the 
assessment of treatment results in pregnant women with 
diagnosed anemia caused by iron deficiency with the use 
of EPO, as well as possible side effects. Literature provides 
data regarding the use of EPO together with Fe preparations 
in the treatment of postpartum anemia.
We have to remember that biological EPO activity reach-
es beyond hematological changes. Many studies have dem-
onstrated that cytokine has autocrine and paracrine effect 
on other tissues showing neuroprotective, anti-inflamma-
tory, and antioxidant activity; it stimulates nitric oxide and 
intensifies angiogenesis [4, 5]. 
Currently, apart from the interest of the effect of EPO on 
hematopoiesis, more and more attention in being brought 
to its potential effect on the fetus and the role it plays in 
the development of pregnancy. It was demonstrated that 
the concentration of cytokine in blood of pregnant women 
changes and reaches maximum values around the middle 
of pregnancy, which is probably related to the physiologi-
cal blood hemodilution. Due to the size of the particle, EPO 
does not penetrate the placenta, which was also proved in 
the conditions of experimental perfusion of a fragment of 
placenta in an in vitro test [7, 8]. 
Fetus produces EPO primarily in the liver. Its third source 
during pregnancy is the placenta. Due to the existing sepa-
rate co-parameters for the mother and the fetus and the 
fact that what stimulates its production is hypoxia, the con-
centration of EPO is treated by many authors as a sensitive 
marker of fetal asphyxia [4, 9]. 
Literature points out the increase in the EPO con-
centration in the plasma of the mother during preec-
lampsia, and, according to Hershkovitz et al., the rea-
son for that is the diminished flow through placenta, its 
hypoxia and related to it increased production of EPO 
by the trophoblast’s cells [10]. Although mother’s EPO has 
no effect on the fetus, its potential effect on the placenta 
is unknown, particularly since Resh et al. found in an in 
vitro study a vasoconstrictive effect of EPO on the umbilical 
cells, especially the umbilical vein. However, other scientists 
concentrate on the development of an early pregnancy 
and stress the positive of EPO on the angiogenesis of 
the trophoblast’s cells. Considerable differences have 
been found in the concentration of cytokine in plasm in 
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Table 1. Groups characteristics
Group 1 — Ferrum
N = 12
Group 2 — EPO
N = 13 P
Average Standard deviation Average Standard deviation
Gestational age [w] 28.6 6.47 29.5 4.6 0.8939
Body weight before pregnancy [kg] 66.7 4.83 66.2 10.94 0.7330
Weight gain [kg] 9.7 4.22 9.46 3.59 0.8878
Pregnant women’s age 30.1 5.53 28.8 6.63 0.1425
pregnant women and the expression of EPO-R receptors 
on the trophoblast in cases of regular and pathological 
pregnancies [9, 11]. 
MATERIAL AND METHODS
The study group included 25 patients with gestational 
age between 18 and 35 weeks, treated for treatment-
resistant anemia with the use of oral iron preparations. The 
study was conducted with pregnant women from the 
Pregnant Pathology Department, Medical University of Lodz, 
in 2006–2012. Every patient was informed about possible 
ways of treatment and gave informed consent to iron and 
EPO therapy. The size of the group depended on the number 
of patients with the above mentioned diagnosis hospitalized 
in the ward during that period of time. The patients were 
divided into two groups:
Group I — patients treated with iron preparations 
administered parenterally (Ferrum Lek 1 amp every other day, 
intramuscular). Women with the initial level of hemoglobin 
equal or over 9.2 g%, but not higher than 10.9 g%, were 
placed in this group. 
Group II — patients treated with human recombinant 
erythropoietin (rHuEpo) of 1000 u. intravenously, every three 
days (initial hemoglobin level of HB < 9.2 g%). In this group, 
iron supplementation with oral preparations was also used. 
The reason for that group selection was the profile of 
the patient hospitalized in the pathological pregnancy ward. 
Light and moderate anemias are the most common types of 
disorders found in pregnant women. It seemed reasonable 
to use these two groups of patients to carry out the tests.
In both groups, patients received orally 5 mg of folic 
acid daily. 
All important information, as a standard medical in-
terview, had been collected from the patients before the 
implementation of the treatment. No patient had symptoms 
of eating disorders or used a restrictive or vegetarian diet. 
None of them were under treatment for hypertension or 
chronic infections, either. Before the examination, each 
patient had a blood test, iron concentration in plasma test, 
and a total and latent iron binding capacity tests, in order to 
corroborate the diagnosis of deficiency anemia. A follow-up 
test of the erythrocytic system was performed again in the 
eighth day of the treatment. 
Afterwards, the differences in the values of particular 
parameters in relation to the test results from before the 
treatment were assessed. Those differences were marked as 
д. Treatment effectiveness was compared taking into account 
the concentration of hemoglobin and the numerical value of 
erythrocytes. The general condition of the pregnant women 
and the well-being of the fetuses were supervised with the 
use of cardiotocographic data and fetal motor activity. 
Statistical analysis
The statistical analysis was performed with the use 
of a computer program named Statistica 12. In order to 
assess the normality of distribution, Shapiro-Wilk test 
was used, whereas equality of variances was tested using 
Brown – Forsythe test. The comparisons between the groups 
were conducted using t-Student, Mann – Whitney U, and 
chi2 tests. P < 0.05 was adopted as the level of statistical 
significance 
RESULTS
Results obtained in the compared groups can be 
observed in the table below. 
The evaluated factors were: pregnant women’s age, 
body weight, weight gain during pregnancy (Tab. 1).
The parameters of the erythrocytic system, platelets, 
and leucocytes were assessed, and the results can be found 
in Table 2.
In accordance with the assumed method of the patients’ 
placement in groups, the average hemoglobin concentration 
was lower in Group II in comparison to Group I (p = 0.0011). 
However, when taking into account the average number of 
erythrocytes in patients of both groups before treatment, no 
significant statistical difference was observed (p = 0.1628).
Table 3 presents the obtained differences of the formerly 
assessed parameters 7 days into the treatment, illustrated 
as Д.
One week into the treatment, 33.3% of the tested 
patients from Group I and 92.3% of those from Group II 
(p < 0.005) responded to the treatment positively. 
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Comparing the results obtained after the treatment, 
it was demonstrated that the patients from Group II, who 
were treated with EPO, had a significantly higher average 
hemoglobin and erythrocytes growth than the pregnant 
women in Group I, who were treated exclusively with an iron 
preparation. 
Besides, it was found that the growth of hemoglobin 
concentration after the treatment was not related to the 
age of the woman (Pearson coefficient value r = 0.07) or 
the gestational period (r = 0.08). A negative correlation 
was noticed though between the initial hemoglobin 
concentration before the treatment and its growth after 
the research was concluded (r = 0.602). 
Only one patient from Group II demonstrated a short-
term temporary increase of blood pressure to the value of 
150/94 mm Hg. No pathological reactions in the pregnant 
women’s bodies to the administered erythropoietin or any 
threat to the fetus in any pregnant women were observed. 
The research draws attention to the important and 
often forgotten pregnancy pathology which is anemia. 
The presented study has numerous limitations, caused 
mainly by the number of patients participating in it, but it 
shows promising data for research in the future. It is worth 
mentioning that future studies should include patients with 
severe anemia.
DISCUSSION
Due to the high prevalence and the consequences 
it has for both the mother and the fetus, anemia caused 
by iron deficiency constitutes a significant problem in 
modern perinatology. The traditional treatment method 
involves leveling the quantity of iron in the body through its 
supplementation administered orally. In case of suspected 
problems with iron assimilation in the gastrointestinal tract, 
it should be administered parenterally. 
The normalization of existing iron deficiency from before 
pregnancy requires time and it also depends on a patient’s 
acceptance and her cooperation with medications and 
diet. If the treatment results are ineffective, a blood 
transfusion can be an alternative, which, however, can cause 
numerous undesirable post-transfusion complications, 
both immediate and remote. Moreover, for a large group 
of women, treatment with blood derivatives is unacceptable 
for religious reasons. This is why the use of EPO with pregnant 
women has become a promising method of therapy in the 
treatment of anemia. 
The results of the performed study were assessed one 
week into the treatment. The positive effect was reached in 
92.3% of women treated with iron + EPO, but only in 33.3% 
of those who received only iron. Positive results were also 
obtained by Breymann et al. [12], who stress that treatment 
with both iron only and iron plus EPO are effective; however, 
pregnant women who were given the combination of both 
reached the desired level of hemoglobin, i.e. 11 g/dL, sooner. 
Similar good results are presented by Krafft et al. [13], who 
simultaneously point out the need to search for the causes 
why some patients did not show any improvement after 
being treated with the same iron preparations, despite 
being diagnosed with deficiency anemia. Many authors 
report positive effects of using EPO in the treatment of 
anemia in pregnant women. Sifakis et al. [14] report a quick 
positive reaction to the treatment in 73% of the pregnant 
Table 2. Parameter values in peripheral blood
Group 1 — Ferrum
N = 12
Group 2 — EPO
N- = 13 P
Average Standard deviation Average Standard deviation
WBC [thous.] 9.73 3.16 10.05 2.39 0.7927
Erythrocytes [mln] 3.58 0.65 3.15 0.41 0.1628
Hb [g/dL] 9.83 1.15 8.52 0.62 0.0011
PLT [thous.] 233.1 55.05 269.2 97.14 0.3143
Table 3. Differences of evaluated parameters
Group 1 — Ferrum
N = 12
Group 2 — EPO
N- = 13 P
Average Standard deviation Average Standard deviation
Д WBC [thous.] 1.45 1.94 0.61 2.68 0.3671
Д Erytrocyty [mln] 0.2 0.52 0.22 0.29 0.0235
Д Hb [g/dL] 0.2 0.61 0.69 0.59 0.0436
Д PLT [thous.] 26.73 40.27 3.76 95.66 0.7098
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women, observing an increase of the Hb (haemoglobin) 
concentration by 3 g/dL in the first two weeks.
From among the patients treated with EPO, one had 
an excessive increase of blood pressure, which could have 
been an example of undesirable side effects.
As noted by Fisher, the administration of EPO may carry 
the risk of adverse side effects, especially hypertension and 
prothrombotic action [11]. Patomechanism of this disorder 
consists in the retention of Ca ions in the intercellular space 
and decrease of the reactivity to the vasodilatory effect of ni-
tric oxide. According to Fisher, EPO may stimulate increased 
production of endothelin and changes in the production 
of prostacyclin and may foster the production of renin and 
angiotensin [15]. In existing literature, however, there are 
no data on serious complications in mothers during the 
EPO treatment. In our study, we have observed only once 
an increase of blood pressure in the pregnant women- one 
patient demonstrated a short-term temporary increase of 
blood pressure to the value of 150/94 mm Hg. Single re-
ports found in literature concern cases of some significant 
increase of blood pressure after the administration of EPO; 
however, they occurred to women with prior chronic renal 
disease [11]. 
Literature provides data regarding the use of EPO 
together with Fe preparations in the treatment of post-
partum anemia. Wagstrom et al. compared the results of 
treatment of pregnant women given iron only and those 
given iron + EPO. They did not observe any significant dif-
ferences and both methods proved effective [11]. On the 
other hand, Meyer found in pregnant women treated with 
EPO less severe symptoms of baby blues in comparison to 
the patients treated exclusively with Fe [16]. 
The research draws attention to important and often 
forgotten pregnancy pathology, which is anemia. Presented 
study has numerous limitations, caused mainly by the 
number of patients participating, but shows promising 
data for research in the future. It is worth mentioning that 
future studies should include patients with severe anemia.
Erythropoietin is a cytokine not entirely explored in 
the context of its application in pregnant women. Its basic 
use as a substance assisting erythropoiesis in the treat-
ment of patients with anemia is rather well explored and 
often practised with a good result. On the basis of the avail-
able literature and our own research, it should be regarded 
as a valuable form of therapy. Positive effects of EPO as 
a medication normalizing hemoglobin and erythrocyte 
levels concern a great majority of the treated patients and 
so far no severe negative effects have been found. Further 
research regarding the significance of erythropoietin should 
be conducted as it seems that there are considerably higher 
possibilities of the application of this cytokine in therapy 
than currently used.
CONCLUSIONS
Erythropoietin administered together with the oral dose 
of iron in pregnant women with anemia caused by iron 
deficiency shows higher effectiveness than the therapy 
with the use of iron preparations administered parenterally. 
The treatment with the use of erythropoietin during 
pregnancy is not related to any dangerous side effects for 
the mother or the fetus. 
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